NDAORALCONCENTRATE
Approved
Dec 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
TRILAFON (perphenazine) by Merck & Co. is clinical pharmacology pharmacokinetics following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. Approved for schizophrenia, psychotic disorders. First approved in 1958.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRILAFON (perphenazine) is a first-generation antipsychotic approved in 1958 for schizophrenia and psychotic disorders. It works by antagonizing dopamine receptors in the central nervous system. The drug is administered orally as a concentrate and undergoes extensive hepatic metabolism with a 9-12 hour half-life.
LOE Approaching
As a legacy antipsychotic approaching loss of exclusivity, the brand team is likely contracting with reduced commercial headcount and focus on cost-optimization strategies.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics Following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours. The plasma elimination half-life of perphenazine was independent of dose and ranged between 9 and 12 hours. In a study in…
Indications (2)
Worked on TRILAFON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.